Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

NCT02290951 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: Odronextamab multiple dose levels
DRUG: Odronextamab multiple dose levels

Sponsor

Regeneron Pharmaceuticals